Mulligan Mobilization in Rheumatoid Hand

Kirsehir Ahi Evran Universitesi21 enrolled

Overview

The goal of this randomized-controlled study is to learn about the effectiveness of the Mulligan mobilization in rheumatoid hands. The main question it aims to answer are: -Does mulligan mobilization reduce effusion in wrist joints with rheumatoid arthritis? Participants will take Mulligan mobilization application and active ROM exercises for their hands. Researcher will compare treatments group ith sham mobilization.

Rheumatoid arthritis (RA) is a systemic disease that can lead to chronic pain, bone and soft tissue damage, and disability retirement. Alleviating pain and maintaining joint range of motion in RA are important for reducing disability. Joint mobilizations are manual therapy techniques used to increase range of motion and reduce pain. The aim of this study is to investigate the effects of rheumatoid hand exercise and protective approach and joint mobilization applications on pain, functional status and quality of life.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Rheumatoid Arthritis

Interventions

Mulligan MobilizationOTHER

Mobilization with movement (MWM) is the concurrent application of sustained accessory mobilization applied by a therapist and an active physiological movement to end range applied by the patient. Passive end-of-range overpressure, or stretching, is then delivered without pain as a barrier.

Eligibility

Sex: ALLMin age: 30 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Having been diagnosed with RAS according to ACR and EULAR criteria, * Being under the control of a physiatrist for at least 1 year, * Have not had any upper extremity surgery in the last 6 months * Have the cognitive capacity to understand commands, * Not to be involved in any other rehabilitation program or study, Exclusion Criteria: * Presence of soft tissue injury and chronic bone damage in the hand, * Presence of acute inflammation in any joint in the previous week, * Presence of a degenerative or non-degenerative neurological condition that causes a change in pain perception,

Locations (1)

Ahi Evran University

Kırşehir, Turkey (Türkiye)

Outcomes

Primary Outcomes

Joint activity

Primary outcomes included the automated quantification (Q) of joint activity using color Doppler pixel count calculations (% hyperemia/blood flow activity score within an inflamed joint: color Q-Doppler MCP/region)

Time frame: 6 weeks

Amount of hypertrophia and effusion in wrist joints

Synovial fluid (area of hypertrophy and effusion, mm2: synovial fluid MCP/region)

Time frame: 6 weeks

Distance in wrist joints

the radiographic distance (mm) between the MCP or interphalangeal bone space (joint space MCP/region)

Time frame: 6 weeks

DAS-28

High disease activ ity \>5.1, low disease activity ≤ 3.2, remission ≤ 2.6

Time frame: 6 weeks

Secondary Outcomes

Determining the state of pain after treatment

Pain will be assessed using the Mcgill-Melzack Pain Questionnaire

Time frame: 6 weeks

Grip force

Hand grip strength will be measured with a pinch meter and a dynamometer

Time frame: 6 weeks

Range of Motion

Range of Motion will be measured with goniometer

Time frame: 6 weeks

Post-treatment status of disease-related quality of life

Quality of life was assessed using the Rheumatoid Arthritis Quality of Life (RAQoL).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.